Relmada Therapeutics Raises $160M in Oversubscribed PIPE Financing — Relmada Therapeutics, Inc.

Event summary

Relmada Therapeutics secured $160M in a private placement financing, oversubscribed by investors.
The deal includes 29.47M shares of common stock at $4.75 per share and pre-funded warrants for 4.21M shares at $4.749 per warrant.
Proceeds will fund working capital and R&D for oncology and CNS therapies, including lead candidates NDV-01 and sepranolone.
The transaction is expected to close on or about March 11, 2026, subject to customary closing conditions.

The big picture

Relmada's $160M PIPE financing underscores the continued appetite for clinical-stage biotech investments, particularly in high-impact therapeutic areas like oncology and CNS disorders. The oversubscription suggests strong investor backing, but the real test will be how effectively the company leverages these funds to drive its pipeline forward in a competitive and capital-intensive sector.

What we're watching

Execution Risk: How Relmada will deploy the $160M to advance its pipeline, particularly NDV-01 and sepranolone, amid competitive biotech landscapes.
Market Dynamics: Whether the oversubscription reflects sustained investor confidence in Relmada's clinical-stage assets or broader biotech sector optimism.
Strategic Priorities: The pace at which Relmada can translate financing into tangible clinical milestones, given the capital-intensive nature of oncology and CNS drug development.